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BACKGROUND: Despite effective lowering of low density lipoprotein cholesterol 
(LDL-C) with statin for prevention of cardiovascular events, risk remains high in those 
with mixed dyslipidemia. OBJECTIVES: To examine the prevalence of dyslipidemia 
before and after lipid modifying therapy (LMT) use in Thailand. METHODS: We 
recruited 807 patients (mean age 59 and 45.2% male) who, between January 2001 
and June 2007, aged ≥35 years, initiated LMT, had ≥1 lipid abnormality and follow-up 
>12 months after initiating LMT, with a complete lipid panel (LDL-C, high density 
lipoprotein cholesterol [HDL-C] and triglycerides[TG]) before and 12 months after 
therapy. Patients with coronary heart disease (CHD), type 2 diabetes or a 10-year 
CHD risk >20% were classiﬁ ed as high (cardiovascular) risk patients. Threshold levels 
for LDL-C, HDL-C and triglycerides were speciﬁ ed as per NCEP ATPIII Guidelines. 
RESULTS: At baseline, 65%, 34%, and 43% exhibited elevated LDL-C, elevated TG, 
and low HDL-C, respectively while 35% had elevated LDL-C alongside low HDL-C 
and/or elevated TG. Among high-risk patients (n = 430), 68%, 35%, and 44% exhib-
ited elevated LDL-C, elevated TG and low HDL-C, respectively; while 38% had 
elevated LDL-C alongside low HDL-C and/or elevated TG. Among the sample, 77% 
were on statins, 7% on ﬁ brates, and 13% on both. After 12 months, 21%, 32%, and 
39% of patients still had elevated LDL-C, elevated TG and low HDL-C, while 18% 
had elevated LDL-C alongside low HDL-C and/or elevated TG. High-risk patients had 
similar degrees of persistent dyslipidemia with 27%, 25%, 44%, and 21% experienc-
ing elevated LDL-C, elevated TG, low HDL-C, and elevated LDL-C alongside low 
HDL-C and/or elevated TG, respectively. CONCLUSIONS: This cohort had improved 
LDL-C levels after therapy, with no improvement of TG and HDL-C levels among 
the overall, and moderate and negligible among the high-risk population, respectively. 
These patients may beneﬁ t from other types of LMT. 
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OBJECTIVES: To assess average amount of life-years lost due to death from pulmo-
nary embolism (PE) conﬁ rmed by autopsy in patients hospitalized at internal medicine 
department. METHODS: In our prospective observation we analyzed all fatal cases 
at Second Department of Internal Medicine at University Hospital Bratislava, where 
cause of death was veriﬁ ed by autopsy during the period from 1983 till 2005. Age, 
sex, clinical diagnosis, and pulmonary embolus ﬁ nding from autopsy were recorded 
for each case. Sex adjusted life expectancy for each calendar year (1983–2005) was 
used from ofﬁ cial statistical sources available for Slovakia and lost years of life were 
calculated accordingly. RESULTS: There were 1375 deaths and in 70% (n = 963) 
autopsy was performed during the observational period of 23 years. Fatal PE was 
found in 12% of cases (n = 118), from which 64 cases were not clinically diagnosed 
prior to autopsy. Average age for group with conﬁ rmed PE (n = 118) was 76.5 years 
(interval 38–96) with 54 (46%) males and 64 (54%) females. As calculated from life 
expectancy data, there were 939 life-years lost due to fatal PE veriﬁ ed by autopsy. In 
average 42.7 years of life (95% CI 32.8–52.6) were lost each year. CONCLUSIONS: 
Results of our study shows that PE continues to be important cause of mortality in 
hospitalized patients, accounting for 12% of deaths at internal department. In average 
42.7 years of life were lost each year in one medical department due to PE. Despite 
the advances in diagnostic methods and thromboprophylaxis of VTE during the past 
decades, lost of life-years caused by fatal PE are still signiﬁ cant among medically ill 
patients in the period from 1983 till 2005. 
CARDIOVASCULAR DISORDERS – Cost Studies
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OBJECTIVES: This study is to estimate potential cost savings by reducing the inci-
dence of two major smoking-related illnesses—chronic obstructive pulmonary disease 
(COPD) and coronary heart disease (CHD)—through successful smoking cessation 
among insured Chinese population. METHODS: A predictive economic model was 
constructed upon a hypothetical cohort of insured patients to assess cost savings of 
an oral smoking cessation drug (varenicline) in terms of reduced COPD/CHD inci-
dence over 15 years (at 5-year intervals). The size of the cohort was determined by 
COPD/CHD prevalence, COPD/CHD population attributable to smoking and per-
centage of patients insured drawn from public information and literature, and data 
of smokers’ willingness to use oral smoking cessation drugs obtained from internal 
market survey. Medical treatment costs of varenicline were estimated according to 
current pricing scheme. Cost-savings at different intervals were estimated using param-
eters of successful tobacco abstinence rate calculated from varenicline clinical trials, 
risk reduction of COPD/CHD drawn from literature, and annual management costs 
of COPD/CHD patients obtained from provincial health insurance database. Sensitiv-
ity analysis on tobacco abstinence rate in varenicline users was also performed. Overall 
cost-savings were then estimated combining medical treatment costs of varenicline and 
associated cost-savings together. Cost-savings due to reduced disease risk are calcu-
lated at each 5-year interval. RESULTS: A total of 19,583 subjects are included in 
our cohort. Costs of completed varenicline cycles are estimated to be RMB 42 million. 
At the ﬁ rst year, medical costs for varenicline outweigh the savings by around RMB 
32 million. However, increased cost savings are observed at Year 5, 10, and 15, 
ranging from RMB 25–27 million, RMB 120–126 million, RMB 242–253 million, 
respectively. CONCLUSIONS: Successful smoking cessation through varenicline treat-
ment could lower the burden of smoking-related illness in China, and its associated 
cost savings are substantial to the society in the long run. 
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OBJECTIVES: This study is to estimate health expenditures in hypertension and dys-
lipidemia (HTN/DYS) patients with cardiovascular risks over a period of 10 years in 
Chinese health-care settings. Costs are compared among patients using single pill 
amlodipine/atorvastatin (SPAA) therapy, amlodipine therapy only, and no intervention. 
METHODS: Three hypothetical cohorts of HTN/DYS patients were constructed: 1) 
SPAA group; 2) amlodipine only group; and 3) no intervention group. The size of eligible 
population was determined by national prevalence data on patients with HTN/DYS 
and those not receiving statin therapies, and on percentage of patients currently insured 
derived from total publication. For each group, data on risk of having cardiovascular 
illness over 10 years, average costs for cardiovascular illness management per patient, 
and average costs for HTN/DYS treatment per patient were identiﬁ ed from existing 
literature. Overall health expenditures were then calculated by costs of having cardio-
vascular illness within 10 years, plus costs of treating HTN/DYS over 10 years. Com-
parisons were made between SPAA versus amlodipine only, and SPAA versus no 
intervention. RESULTS: Of the 26.89 million eligible patients included in this study, 
the overall health expenditures over 10 years in patients with SPAA therapy, amlodipine 
only, and no intervention were estimated to be RMB 37.65 billion, RMB 59.17 billion 
and RMB 75.30 billion, respecbtively. The SPAA therapy allows payers to save annual 
cost of 2.15 billion when compared with amlodipine only therapy, and annual cost of 
3.77 billion when compared with no intervention at all. CONCLUSIONS: SPAA 
therapy in HTN/DYS patients is likely to generate more cost savings to the society by 
reducing the costs of cardiovascular illness, when compared with traditional 
therapies. 
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OBJECTIVES: Previous evidence has shown that using Angiotensin Converting 
Enzymes (ACEIs) or Angiotensin Receptor Blockers (ARBs) results in decreased mor-
bidity among patients with chronic heart failure (CHF). However, the beneﬁ ts earned 
from medications depend on the amount of medications supplied and used. This study 
aims to determine the effects of medication supplies on health-care costs and hospi-
talizations in CHF patients receiving ACEIs or ARBs. METHODS: We retrospectively 
examined an electronic patient database in a provincial hospital located in the north 
of Thailand. All patients with an ICD-10 of I-50.0 (CHF) receiving either ACEIs or 
ARBs from January to December, 2003 were included. Their medication supplies were 
assessed using Medication Possession Ratio (MPR) method during the study period 
following the index date. The association between medication supply (appropriate: 
MPR 0.8–1.20, oversupply: MPR >1.20, undersupply: MPR <0.8) and all-cause rehos-
pitalizations within 1 year was determined using Cox-proportional hazard model. 
Total direct health-care cost was compared between all groups using multiple linear 
regressions. All analyses were adjusted for propensity score (PS) and other variables 
including age, sex, prior health-care use, and insurance status. RESULTS: Among 
1012 CHF patients, 389 received ACEIs or ARBs. The mean age was 66 years with 
56% female. Forty-two percent were undersupplied, while 56% and 2% were appro-
priately supplied and oversupplied respectively. The adjusted hazard ratios of under 
and oversupply for all-cause rehospitalizations were 1.21 (95% CI; 0.79–1.86) and 
3.90 (95% CI; 0.89–17.06). Comparing with the group appropriately supplied, total 
direct medical cost in the undersupplied group was signiﬁ cantly higher at 11,027 baht 
(95%CI; 325–21,727), while non-signiﬁ cant trend in the oversupply group was 
observed. CONCLUSIONS: Under medication supply is signiﬁ cantly associated with 
higher health-care cost in patients with chronic heart failure. 
